Krystal Biotech, Inc. Common Stock KRYS
Analyst Ratings
- Consensus
- Buy — 10 Buy · 1 Hold · 0 Sell (11 analysts)
- Avg. Price Target
- $355.10 (+5.4% upside)
Key Stats
- Today's Range
- $334.99 – $343.14
- 50-Day Range
- $297.02 – $382.54
- 52-Week Range
- $130.50 – $382.54
- Volume
- 197K shs
- Average Volume
- 496K shs
- Market Cap
- $10.16 billion
- P/E Ratio
- 42.23
- Dividend Yield
- —
Valuation
- P/E Ratio
- 42.23
- Price / Book
- 7.48
- Price / Sales
- 23.07
Short Interest
- Short Interest
- 0.11%
- Days to Cover
- 1.51
Financials (TTM)
- Revenue
- $440.48 million
- Net Income
- $241.47 million
- Net Margin
- 54.82%
- Return on Equity
- 17.77%
- Debt-to-Equity
- —
About Krystal Biotech, Inc. Common Stock
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
Related Stocks
Compare head-to-head: KRYS vs AMGN·KRYS vs MRNA·KRYS vs HALO·KRYS vs KYMR
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.